

WHO Expert Committee on Biological Standardization

Sixty-sixth report



World Health
Organization

The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications.

The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences.

To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective – the attainment by all people of the highest possible level of health.

The *WHO Technical Report Series* makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO.

For further information, please contact: WHO Press, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int; order on line: www.who.int/bookorders).

W H O T e c h n i c a l R e p o r t S e r i e s
9 9 9

WHO Expert Committee on Biological Standardization

Sixty-sixth report

*This report contains the collective views of an international group of experts and
does not necessarily represent the decisions or the stated policy of the World Health Organization*



**World Health
Organization**

WHO Library Cataloguing-in-Publication Data:

WHO Expert Committee on Biological Standardization, sixty-sixth report.

(WHO technical report series ; no. 999)

1. Biological Products - standards. 2. Vaccines - standards. 3. Blood - standards.
4. Anti-Bacterial Agents - standards. 5. Reference Standards. 6. Diagnostic Test Approval.
I. World Health Organization. II. WHO Expert Committee on Biological Standardization
(2015: Geneva, Switzerland). III. Series.

ISBN 978 92 4 120999 1

(NLM classification: QW 800)

ISBN (PDF) 978 92 4 069563 4

ISSN 0512-3054

© World Health Organization 2016

All rights reserved. Publications of the World Health Organization are available on the WHO website (<http://www.who.int>) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO website (http://www.who.int/about/licensing/copyright_form/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of the World Health Organization.

Printed in Italy

Contents

Abbreviations	xv
1. Introduction	1
2. General	4
2.1 Current directions	4
2.1.1 Strategic directions in biological standardization: WHO priorities	4
2.1.2 Blood products and related in vitro diagnostics: recent and planned activities in biological standardization	5
2.1.3 Vaccines and biotherapeutics: recent and planned activities in biological standardization	7
2.2 Reports	9
2.2.1 Report from the WHO Blood Regulators Network	9
2.2.2 Report of the fifth meeting of WHO collaborating centres to support the development of WHO biological reference preparations for in vitro diagnostic devices	10
2.2.3 Report from the network of WHOCCs for the standardization and evaluation of vaccines	12
2.2.4 Report of a WHO informal consultation on international standards for biotherapeutic products	13
2.3 Feedback from custodian laboratories	15
2.3.1 Developments and scientific issues highlighted by custodians of WHO biological reference preparations	15
2.4 Cross-cutting activities of other WHO committees and groups	21
2.4.1 Update on matters arising from the International Nonproprietary Names Expert Group	21
2.4.2 Collaborative procedure for facilitating national registration of WHO prequalified medicinal products	22
2.4.3 Proposal to transition from microbiological to physicochemical assays for antibiotic potency testing	23
2.4.4 Labelling information for influenza vaccines intended for use in pregnant women	25
2.4.5 Influenza vaccine response during the start of a pandemic	26
3. International Recommendations, Guidelines and other matters related to the manufacture and quality control of biological substances	28
3.1 General	28
3.1.1 WHO good manufacturing practices for biological products	28
3.1.2 Update on the development of a candidate control material for adventitious virus detection using deep sequencing	29
3.2 Biotherapeutics other than blood products	30
3.2.1 Regulatory assessment of approved rDNA-derived biotherapeutics	30
3.3 Blood products and related substances	31
3.3.1 Ebola-related issues	31
3.3.2 Local production of blood products	32
3.3.3 Residual risk of virus infections caused by blood products	33
3.3.4 WHO general assessment tool for conducting gap analysis of national regulatory systems for health products and technologies	34

3.4	In vitro diagnostic device reagents	35
3.4.1	Calibration of secondary standards for in vitro diagnostic devices	35
3.4.2	WHO prequalification of in vitro diagnostic devices	36
3.5	Vaccines and related substances	37
3.5.1	Recommendations to assure the quality, safety and efficacy of recombinant human papillomavirus virus-like particle vaccines	37
3.5.2	Guidelines on the stability evaluation of vaccines for use under extended controlled temperature conditions	38
3.5.3	Vaccine evaluation in public health emergencies – review of regulatory pathways in selected countries	39
3.5.4	Development of Guidelines on the quality, safety and efficacy of Ebola vaccines	40
3.5.5	Revision of Guidelines on the safe production and quality control of inactivated poliomyelitis vaccines manufactured from wild polioviruses	41
3.5.6	International collaborative study to assess the utility of deep sequencing in the quality control of oral poliomyelitis vaccines and inactivated poliomyelitis vaccines made from Sabin strains	42
4.	International Reference Materials – antibiotics	44
4.1	WHO International Standards and Reference Reagents – antibiotics	44
4.1.1	Fourth WHO International Standard for streptomycin	44
5.	International reference materials – biotherapeutics other than blood products	45
5.1	WHO International Standards and Reference Reagents – biotherapeutics other than blood products	45
5.1.1	First WHO International Standard for tumour necrosis factor receptor Fc fusion protein (etanercept)	45
5.1.2	First WHO Reference Panel for antibodies to erythropoietin (human)	46
5.2	Proposed new projects and updates – biotherapeutics other than blood products	47
5.2.1	Proposed First WHO International Standard for darbepoetin	47
5.2.2	Proposed First WHO Reference Panel for in vitro bioassay of erythropoietin (EPO)	47
5.2.3	Proposed First WHO international standards for pegylated-interferon- α -2a and pegylated-interferon- α -2b	48
5.2.4	Proposed First WHO Reference Reagent for TGN1412-like functional activity	49
5.2.5	Proposed First WHO Reference Reagent for Pam ₃ CSK ₄	49
5.2.6	Proposed stability monitoring of the First WHO International Standard for pegylated granulocyte colony-stimulating factor	50
6.	International reference materials – blood products and related substances	51
6.1	WHO International Standards and Reference Reagents – blood products and related substances	51
6.1.1	First WHO Reference Reagent for anti-A and anti-B in serum and plasma for use in haemagglutination assays	51
6.1.2	Fifth WHO International Standard for blood coagulation factor IX (concentrate)	52
6.2	Proposed new projects and updates – blood products and related substances	53
6.2.1	Proposed First WHO International Standard for activated blood coagulation factor X	53

6.2.2	Proposed First WHO Reference Panel for procoagulant activity of human immunoglobulin	54
6.2.3	Proposed Fifth WHO International Standard for thromboplastin (human, recombinant)	55
6.2.4	Proposed Fifth WHO International Standard for thromboplastin (rabbit, plain)	56
7.	International reference materials – In vitro diagnostic device reagents	57
7.1	WHO International Standards and Reference Reagents – in vitro diagnostic device reagents	57
7.1.1	First WHO International Standard for JC virus DNA for NAT-based assays	57
7.1.2	First WHO International Standard for BK virus DNA for NAT-based assays	58
7.1.3	Fifth WHO International Standard for hepatitis C virus RNA for NAT-based assays	60
7.1.4	Fourth WHO International Standard for anti- <i>Toxoplasma gondii</i> (human)	60
7.1.5	Assignment of a holotranscobalamin value to the First WHO International Standard for vitamin B12 and folate in human serum	62
7.1.6	First WHO International Standard for human C-peptide	62
7.1.7	First WHO Reference Panel for hepatitis E virus genotypes for NAT-based assays	63
7.1.8	Extension of the First WHO Repository of platelet transfusion relevant bacterial strains	65
7.1.9	First WHO Reference Reagent for Ebola virus antibodies	65
7.1.10	First WHO reference reagents for Ebola virus RNA for NAT-based assays	66
7.2	Proposed new projects and updates – in vitro diagnostic device reagents	68
7.2.1	Proposed Fourth WHO International Standard for hepatitis B virus DNA for NAT-based assays	68
7.2.2	Proposed Fourth WHO International Standard for HIV-1 RNA for NAT-based assays	68
7.2.3	Proposed First WHO International Standard for varicella zoster virus DNA for NAT-based assays	69
7.2.4	Proposed First WHO International Standard for <i>Trypanosoma cruzi</i> DNA for NAT-based assays	70
7.2.5	Proposed First WHO International Standard for <i>Plasmodium vivax</i> DNA for NAT-based assays	70
7.2.6	Proposed First WHO International Standard for <i>Plasmodium falciparum</i> antigens	71
7.2.7	Proposed First WHO Reference Panel for KRAS codon 12 and 13 mutations	72
7.2.8	Proposed Fourth WHO International Standard for prolactin (human)	73
7.2.9	Proposed First WHO Reference Panel for hepatitis E virus antibodies	73
7.2.10	Proposed First WHO Reference Panel for HIV-1 p24 antigen	74
7.2.11	Proposed First WHO Reference Panel for <i>Babesia microti</i> antibodies	75
7.2.12	Proposed First WHO Repository of red blood cell transfusion relevant bacterial strains	76
8.	International reference materials – vaccines and related substances	77
8.1	WHO International Standards and Reference Reagents – vaccines and related substances	77
8.1.1	First WHO International Standard for anti-EV71 serum (human)	77

8.1.2	First WHO international standards for meningococcal serogroups A and X polysaccharide	78
8.1.3	Third WHO International Standard for diphtheria toxoid for use in flocculation test	79
8.2	Proposed new projects and updates – vaccines and related substances	80
8.2.1	Proposed First WHO international standards for meningococcal serogroups W and Y polysaccharide	80
8.2.2	Proposed First WHO international standards for Vi polysaccharide	81
8.2.3	Proposed First WHO International Standard for anti-Vi polysaccharide serum (human)	82
8.2.4	Proposed First WHO Reference Panel for non-typhoidal salmonella O-antigen polysaccharides	82
8.2.5	Proposed First WHO international standards for antibodies (human) to <i>Salmonella enterica</i> serovars Typhimurium (O4,5 LPS) and Enteritidis (O9 LPS)	83
8.2.6	Proposed First WHO International Standard for <i>Salmonella enterica</i> serovar Paratyphi A O2 polysaccharide	83
8.2.7	Proposed First WHO International Standard for antibodies (human) to <i>Salmonella enterica</i> Paratyphi A O2 polysaccharide	84
8.2.8	Proposed First WHO Reference Panel for O-antigen polysaccharides for <i>Shigella</i> strains	84
8.2.9	Proposed First WHO Reference Panel for anti- <i>Shigella</i> O-antigen polysaccharide serum (human)	85
8.2.10	Proposed First WHO International Standard for anti- <i>Clostridium difficile</i> serum (human)	86

Annex 1

WHO Recommendations, Guidelines and other documents related to the manufacture and quality control of biological substances used in medicine	87
--	----

Annex 2

WHO good manufacturing practices for biological products	93
Replacement of Annex 1 of WHO Technical Report Series, No. 822	93

Annex 3

Regulatory assessment of approved rDNA-derived biotherapeutics	131
--	-----

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/report>